Abstract Details

Title A Randomized, Placebo-Controlled, Dose-Ranging Study To Determine the Efficacy, Safety, and Tolerability of Perampanel, a Selective AMPA Receptor Antagonist, in Patients with Advanced Parkinson[apos]s Disease

Topic Movement Disorders

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Wolfgang H. Oertel, MD, FAAN (Philipps-University Marburg)	Dr. Oertel has received personal compensation for serving as an employee of ParkinsonFonds Deutschland. Dr. Oertel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IntraBio, UK. Dr. Oertel has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for MODAG Germany. The institution of Dr. Oertel has received research support from Stichting ParkinsonFonds, The Netherlands,. The institution of Dr. Oertel has received research support from Michael J Fox Foundation.
	No disclosure on file
David C. Squillacote, MD (David Squillacote MD)	No disclosure on file
Zulfi Haneef, MD, MBBS, MRCP, FAAN	Dr. Haneef has nothing to disclose.

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��